Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CytomX Therapeutics
Biotech
Astellas ends $1.6B biobucks TCE pact with CytomX after 6 years
Astellas is ending its six-year, $1.6 billion biobuck partnership with CytomX Therapeutics aimed at exploring TCE bispecifics.
Will Maddox
Mar 16, 2026 10:12am
Former Aurion chief vaults to Valitor—Chutes & Ladders
Oct 24, 2025 8:30am
CytomX reports patient death from kidney injury in ADC trial
Aug 14, 2025 6:45am
Amgen, CytomX ax T-cell engager after assessing data, priorities
Mar 7, 2025 5:39am
J&J vet jumps to Affinia—Chutes & Ladders
Feb 7, 2025 8:30am
CytomX lays off 40%, mulls future of Amgen-partnered drug
Jan 7, 2025 7:56am
